EGFR and neoplasm: Recent studies are leaning towards lower PD-L1 expression in EGFR-mutant tumors in comparison to smoking-related cancers, which are well infiltrated with T cells, have higher tumor mutational burden (TMB), and longer survival [40,41,42].